Published in J Clin Oncol on November 15, 2004
Oxidative stress, inflammation, and cancer: how are they linked? Free Radic Biol Med (2010) 7.31
Inflammation and cancer: interweaving microRNA, free radical, cytokine and p53 pathways. Carcinogenesis (2009) 3.40
DNMT1 genetic polymorphisms affect breast cancer risk in the central European Caucasian population. Clin Epigenetics (2013) 2.20
Detection and mapping of 5-methylcytosine and 5-hydroxymethylcytosine with nanopore MspA. Proc Natl Acad Sci U S A (2013) 2.09
Posttranslational protein modification in Archaea. Microbiol Mol Biol Rev (2005) 1.86
DNA methylation profiling reveals novel biomarkers and important roles for DNA methyltransferases in prostate cancer. Genome Res (2011) 1.85
Epigenetic modulation of MAGE-A3 antigen expression in multiple myeloma following treatment with the demethylation agent 5-azacitidine and the histone deacetlyase inhibitor MGCD0103. Cytotherapy (2010) 1.50
Aberrant DNA methylation in hereditary nonpolyposis colorectal cancer without mismatch repair deficiency. Gastroenterology (2010) 1.46
Coordinated activation of candidate proto-oncogenes and cancer testes antigens via promoter demethylation in head and neck cancer and lung cancer. PLoS One (2009) 1.45
DNA Methylation Indicates Susceptibility to Isoproterenol-Induced Cardiac Pathology and Is Associated With Chromatin States. Circ Res (2016) 1.44
Methylation mediated silencing of TMS1/ASC gene in prostate cancer. Mol Cancer (2006) 1.38
MeInfoText: associated gene methylation and cancer information from text mining. BMC Bioinformatics (2008) 1.34
Cause and consequences of genetic and epigenetic alterations in human cancer. Curr Genomics (2008) 1.31
Repetitive element hypomethylation in blood leukocyte DNA and cancer incidence, prevalence, and mortality in elderly individuals: the Normative Aging Study. Cancer Causes Control (2010) 1.30
Wnt signalling in human breast cancer: expression of the putative Wnt inhibitor Dickkopf-3 (DKK3) is frequently suppressed by promoter hypermethylation in mammary tumours. Breast Cancer Res (2008) 1.29
Epigenetic changes induced by curcumin and other natural compounds. Genes Nutr (2011) 1.28
In vitro analysis of integrated global high-resolution DNA methylation profiling with genomic imbalance and gene expression in osteosarcoma. PLoS One (2008) 1.24
MicroRNAs in the imprinted DLK1-DIO3 region repress the epithelial-to-mesenchymal transition by targeting the TWIST1 protein signaling network. J Biol Chem (2012) 1.23
Tumor suppressor gene inactivation during cadmium-induced malignant transformation of human prostate cells correlates with overexpression of de novo DNA methyltransferase. Environ Health Perspect (2007) 1.21
Detection and quantification of methylation in DNA using solid-state nanopores. Sci Rep (2013) 1.19
Array-based profiling of reference-independent methylation status (aPRIMES) identifies frequent promoter methylation and consecutive downregulation of ZIC2 in pediatric medulloblastoma. Nucleic Acids Res (2007) 1.19
Integrating Epigenomics into Pharmacogenomic Studies. Pharmgenomics Pers Med (2008) 1.18
Control of carry-over contamination for PCR-based DNA methylation quantification using bisulfite treated DNA. Nucleic Acids Res (2006) 1.17
MethHC: a database of DNA methylation and gene expression in human cancer. Nucleic Acids Res (2014) 1.17
Biological rationale for the use of DNA methyltransferase inhibitors as new strategy for modulation of tumor response to chemotherapy and radiation. Mol Cancer (2010) 1.16
Bookmarking the genome: maintenance of epigenetic information. J Biol Chem (2011) 1.15
Genetic variation in the folate metabolic pathway and risk of childhood leukemia. Blood (2010) 1.14
Integrative discovery of epigenetically derepressed cancer testis antigens in NSCLC. PLoS One (2009) 1.14
Epigenetic inactivation of the tissue inhibitor of metalloproteinase-2 (TIMP-2) gene in human prostate tumors. Oncogene (2007) 1.13
A Bayesian Graphical Model for Integrative Analysis of TCGA Data. IEEE Int Workshop Genomic Signal Process Stat (2012) 1.13
Identifying gene regulatory elements by genomic microarray mapping of DNaseI hypersensitive sites. Genome Res (2006) 1.13
p66alpha and p66beta of the Mi-2/NuRD complex mediate MBD2 and histone interaction. Nucleic Acids Res (2006) 1.12
Potential of DNMT and its Epigenetic Regulation for Lung Cancer Therapy. Curr Genomics (2009) 1.11
K-ras mutation and p16 and preproenkephalin promoter hypermethylation in plasma DNA of pancreatic cancer patients: in relation to cigarette smoking. Pancreas (2007) 1.10
Overexpression and hypomethylation of flap endonuclease 1 gene in breast and other cancers. Mol Cancer Res (2008) 1.10
MethylPurify: tumor purity deconvolution and differential methylation detection from single tumor DNA methylomes. Genome Biol (2014) 1.09
Interplay between cellular methyl metabolism and adaptive efflux during oncogenic transformation from chronic arsenic exposure in human cells. J Biol Chem (2008) 1.06
Mode of action of the chloroethylating and carbamoylating moieties of the prodrug cloretazine. Mol Cancer Ther (2006) 1.05
Mapping the new molecular landscape: social dimensions of epigenetics. New Genet Soc (2013) 1.04
Promoter hypomethylation, especially around the E26 transformation-specific motif, and increased expression of poly (ADP-ribose) polymerase 1 in BRCA-mutated serous ovarian cancer. BMC Cancer (2013) 1.04
Antiproliferation and redifferentiation in thyroid cancer cell lines by polyphenol phytochemicals. J Korean Med Sci (2011) 1.04
Predicting genome-wide DNA methylation using methylation marks, genomic position, and DNA regulatory elements. Genome Biol (2015) 1.03
Advances and Perspectives in the Molecular Diagnosis of Head and Neck Cancer. Expert Opin Med Diagn (2010) 1.03
Epigenetic mechanisms in anti-cancer actions of bioactive food components--the implications in cancer prevention. Br J Pharmacol (2012) 1.03
Comparative analysis of promoter methylation and gene expression endpoints between tumorous and non-tumorous tissues from HCV-positive patients with hepatocellular carcinoma. Mutat Res (2010) 1.03
Association of the maternal MTHFR C677T polymorphism with susceptibility to neural tube defects in offsprings: evidence from 25 case-control studies. PLoS One (2012) 1.01
Genetics and epigenetics of adrenocortical tumors. Mol Cell Endocrinol (2013) 1.01
MBD2 is a critical component of a methyl cytosine-binding protein complex isolated from primary erythroid cells. Blood (2006) 1.01
Epigenetics in hepatocellular carcinoma: an update and future therapy perspectives. World J Gastroenterol (2014) 1.00
Genomic instability in human cancer: Molecular insights and opportunities for therapeutic attack and prevention through diet and nutrition. Semin Cancer Biol (2015) 0.99
Disturbance of circadian gene expression in breast cancer. Virchows Arch (2009) 0.99
MTHFR polymorphisms and breast cancer risk. Arch Med Sci (2011) 0.99
TGF-β induces global changes in DNA methylation during the epithelial-to-mesenchymal transition in ovarian cancer cells. Epigenetics (2014) 0.99
One-carbon metabolism gene polymorphisms and risk of non-Hodgkin lymphoma in Australia. Hum Genet (2007) 0.98
Association of MTHFR gene polymorphisms with breast cancer survival. BMC Cancer (2006) 0.98
Aberrant DNA methylation and prostate cancer. Curr Genomics (2011) 0.98
Methylation of the p16(INK4a) promoter region in telomerase immortalized human keratinocytes co-cultured with feeder cells. Oncogene (2006) 0.97
Fetal globin induction--can it cure beta thalassemia? Hematology Am Soc Hematol Educ Program (2005) 0.97
Ectopic expression of P-cadherin correlates with promoter hypomethylation early in colorectal carcinogenesis and enhanced intestinal crypt fission in vivo. Cancer Res (2008) 0.96
Induction of fetal globin in beta-thalassemia: Cellular obstacles and molecular progress. Ann N Y Acad Sci (2005) 0.96
Methylation of HIN-1, RASSF1A, RIL and CDH13 in breast cancer is associated with clinical characteristics, but only RASSF1A methylation is associated with outcome. BMC Cancer (2012) 0.96
Methylated DNA immunoprecipitation and microarray-based analysis: detection of DNA methylation in breast cancer cell lines. Methods Mol Biol (2009) 0.96
Plant flavone apigenin inhibits HDAC and remodels chromatin to induce growth arrest and apoptosis in human prostate cancer cells: in vitro and in vivo study. Mol Carcinog (2011) 0.95
MDM2 regulates dihydrofolate reductase activity through monoubiquitination. Cancer Res (2008) 0.95
LINE-1 hypomethylation in gastric cancer, detected by bisulfite pyrosequencing, is associated with poor prognosis. Gastric Cancer (2012) 0.95
Decitabine in the treatment of myelodysplastic syndromes. Ther Clin Risk Manag (2007) 0.94
Growth regulation via insulin-like growth factor binding protein-4 and -2 in association with mutant K-ras in lung epithelia. Am J Pathol (2006) 0.93
BORIS binding to the promoters of cancer testis antigens, MAGEA2, MAGEA3, and MAGEA4, is associated with their transcriptional activation in lung cancer. Clin Cancer Res (2011) 0.93
Epigenetics in prostate cancer. Prostate Cancer (2011) 0.92
Identification of GLIPR1 tumor suppressor as methylation-silenced gene in acute myeloid leukemia by microarray analysis. J Cancer Res Clin Oncol (2011) 0.92
Objective and comprehensive evaluation of bisulfite short read mapping tools. Adv Bioinformatics (2014) 0.92
Targeting the epigenome with bioactive food components for cancer prevention. J Nutrigenet Nutrigenomics (2012) 0.91
Epigenetic regulation of HYAL-1 hyaluronidase expression. identification of HYAL-1 promoter. J Biol Chem (2008) 0.91
DNA methylation changes following 5-azacitidine treatment in patients with myelodysplastic syndrome. J Korean Med Sci (2011) 0.90
A statistical method for excluding non-variable CpG sites in high-throughput DNA methylation profiling. BMC Bioinformatics (2010) 0.90
The mechanisms of radiation-induced bystander effect. J Biomed Phys Eng (2014) 0.89
Differential methylation relative to breast cancer subtype and matched normal tissue reveals distinct patterns. Breast Cancer Res Treat (2013) 0.89
Epigenetic regulation of mucin genes in human cancers. Clin Epigenetics (2011) 0.89
Association of hypomethylation of LINE-1 repetitive element in blood leukocyte DNA with an increased risk of hepatocellular carcinoma. J Zhejiang Univ Sci B (2011) 0.88
Understanding the connection between epigenetic DNA methylation and nucleosome positioning from computer simulations. PLoS Comput Biol (2013) 0.88
An empirical Bayes model for gene expression and methylation profiles in antiestrogen resistant breast cancer. BMC Med Genomics (2010) 0.88
Prognostic impact of multidrug resistance gene expression on the management of breast cancer in the context of adjuvant therapy based on a series of 171 patients. Br J Cancer (2006) 0.88
Sox17 promoter methylation in plasma DNA is associated with poor survival and can be used as a prognostic factor in breast cancer. Medicine (Baltimore) (2015) 0.88
Induction of active demethylation and 5hmC formation by 5-azacytidine is TET2 dependent and suggests new treatment strategies against hepatocellular carcinoma. Clin Epigenetics (2015) 0.88
Derepression of Cancer/testis antigens in cancer is associated with distinct patterns of DNA hypomethylation. BMC Cancer (2013) 0.87
Epigenetic effects of green tea polyphenols in cancer. Epigenomics (2013) 0.87
An overview of epigenetic assays. Mol Biotechnol (2007) 0.87
Electrochemical assay for the signal-on detection of human DNA methyltransferase activity. J Am Chem Soc (2013) 0.87
Prioritizing cancer-related genes with aberrant methylation based on a weighted protein-protein interaction network. BMC Syst Biol (2011) 0.87
Targeting tumor suppressor networks for cancer therapeutics. Curr Drug Targets (2014) 0.87
Lung cancer screening: identifying the high risk cohort. J Thorac Dis (2015) 0.86
Genome-wide DNA methylation and gene expression patterns provide insight into polycystic ovary syndrome development. Oncotarget (2014) 0.86
Stable transmission of reversible modifications: maintenance of epigenetic information through the cell cycle. Cell Mol Life Sci (2010) 0.86
Identification of a small optimal subset of CpG sites as bio-markers from high-throughput DNA methylation profiles. BMC Bioinformatics (2008) 0.86
Fractionated radiotherapy is the main stimulus for the induction of cell death and of Hsp70 release of p53 mutated glioblastoma cell lines. Radiat Oncol (2014) 0.86
The role of epigenetics in kidney malignancies. Cent European J Urol (2015) 0.86
Genetic and epigenetic regulation of the organic cation transporter 3, SLC22A3. Pharmacogenomics J (2012) 0.86
The relationship between COPD and lung cancer. Lung Cancer (2015) 0.85
Chromatin immunoprecipitation assay. Biotechniques (2004) 1.68
EGFR targeting of solid tumors. Cancer Control (2007) 1.61
Characterization of CD44v3-containing isoforms in head and neck cancer. Cancer Biol Ther (2006) 1.58
Is adjuvant chemotherapy for bladder cancer safer in patients with an ileal conduit than a neobladder? BJU Int (2005) 1.40
Methylation mediated silencing of TMS1/ASC gene in prostate cancer. Mol Cancer (2006) 1.38
Aberrant promoter methylation of multiple genes in malignant ovarian tumors and in ovarian tumors with low malignant potential. Cancer (2006) 1.24
Soluble CD44 is a potential marker for the early detection of head and neck cancer. Cancer Epidemiol Biomarkers Prev (2007) 1.22
DNA methylation and apoptosis. Mol Immunol (2006) 1.13
Methylation-mediated repression of GADD45alpha in prostate cancer and its role as a potential therapeutic target. Cancer Res (2009) 1.00
Transcriptional regulation by the estrogen receptor of antioxidative stress enzymes and its functional implications. Oncogene (2004) 0.97
Epigenetics in prostate cancer. Prostate Cancer (2011) 0.92
Gynecomastia attributable to human chorionic gonadotropin-secreting giant cell carcinoma of lung. Endocr Pract (2003) 0.91
Outcome after radical cystectomy in patients with clinical T2 bladder cancer in whom neoadjuvant chemotherapy has failed. BJU Int (2009) 0.84
DNA methylation and field cancerization. Epigenomics (2012) 0.84
Neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer: The likelihood of initiation and completion. Indian J Urol (2012) 0.83
Adrenocortical carcinoma with tumor thrombus in the right hepatic vein. Int J Urol (2006) 0.83
5-azacytidine reverses drug resistance in bladder cancer cells. Anticancer Res (2011) 0.83
Methylation-mediated silencing of TMS1 in pancreatic cancer and its potential contribution to chemosensitivity. Anticancer Res (2010) 0.83
Resolution of thrombocytopenia secondary to disseminated intravascular coagulation with docetaxel chemotherapy in prostate cancer. Am J Ther (2012) 0.82
Free circulating DNA as a biomarker of prostate cancer: comparison of quantitation methods. Anticancer Res (2013) 0.82
Serum free circulating DNA is a useful biomarker to distinguish benign versus malignant prostate disease. Cancer Epidemiol Biomarkers Prev (2010) 0.82
Methylation mediated silencing of TMS1 in breast cancer and its potential contribution to docetaxel cytotoxicity. Anticancer Res (2009) 0.80
Epigenetic targets in the diagnosis and treatment of prostate cancer. Int Braz J Urol (2007) 0.80
Prognostic significance of cystoscopy findings following neoadjuvant chemotherapy for muscle-invasive bladder cancer. Can J Urol (2015) 0.79
Methylation-mediated silencing of genes is not altered by selenium treatment of prostate cancer cells. Anticancer Res (2007) 0.79
Hypomethylating agents for urologic cancers. Future Oncol (2011) 0.77
DNA methylation: its role in lung carcinogenesis and therapeutic implications. Expert Rev Anticancer Ther (2005) 0.77
The emerging role of epigenetics in urological cancers. Can J Urol (2007) 0.76
Developmentally regulated demethylase activity targeting the betaA-globin gene in primary avian erythroid cells. Biochemistry (2007) 0.76
Orthotopic ileal neobladder reconstruction for bladder cancer: is adjuvant chemotherapy safe? Int Braz J Urol (2006) 0.75
Methylation state of the prostate specific membrane antigen (PSMA) CpG island in prostate cancer cell lines. Anticancer Res (2002) 0.75